Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Olverembatinib (HQP1351)

HQP1351SJ0003

Ascentage Pharma · Phase 1 · Recruiting · Enrollment 100

NCT03594422

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Olverembatinib 30 to 50 mg every other daySDH-deficient GIST (n = 26)30 to 50 mgSingle armn/rpartial response as best response: 23.1%, cutoff 11.13.2025median progression-free survival: 25.7 months, cutoff 11.13.2025